sars cov 2 2019 ncov spike rbd k417n his recombinant protein  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Name:
    SARS CoV 2 2019 nCoV Spike RBD K417N His Recombinant Protein
    Description:
    A DNA sequence encoding the SARS CoV 2 2019 nCoV Spike RBD K417N His Recombinant Protein YP 009724390 1 Arg319 Phe541 K417N was expressed with a polyhistidine tag at the C terminus
    Catalog Number:
    40592-V08H59
    Price:
    None
    Category:
    recombinant protein
    Product Aliases:
    coronavirus spike Protein 2019-nCoV, cov spike Protein 2019-nCoV, ncov RBD Protein 2019-nCoV, ncov s1 Protein 2019-nCoV, ncov s2 Protein 2019-nCoV, ncov spike Protein 2019-nCoV, NCP-CoV RBD Protein 2019-nCoV, NCP-CoV s1 Protein 2019-nCoV, NCP-CoV s2 Protein 2019-nCoV, NCP-CoV Spike Protein 2019-nCoV, novel coronavirus RBD Protein 2019-nCoV, novel coronavirus s1 Protein 2019-nCoV, novel coronavirus s2 Protein 2019-nCoV, novel coronavirus spike Protein 2019-nCoV, RBD Protein 2019-nCoV, S1 Protein 2019-nCoV, S2 Protein 2019-nCoV, Spike RBD Protein 2019-nCoV
    Host:
    HEK293 Cells
    Buy from Supplier


    Structured Review

    Sino Biological sars cov 2 2019 ncov spike rbd k417n his recombinant protein
    In vitro screening of Abs against <t>SARS-CoV-2</t> variants of concern. (a) Binding to cell-associated spike trimer with the hallmark mutations of the specified variants. (b) ELISA results to plate-adsorbed recombinant spike proteins and (c) heat map summary of ELISA-based reactivity profiles.
    A DNA sequence encoding the SARS CoV 2 2019 nCoV Spike RBD K417N His Recombinant Protein YP 009724390 1 Arg319 Phe541 K417N was expressed with a polyhistidine tag at the C terminus
    https://www.bioz.com/result/sars cov 2 2019 ncov spike rbd k417n his recombinant protein/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike rbd k417n his recombinant protein - by Bioz Stars, 2021-09
    94/100 stars

    Images

    1) Product Images from "Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy"

    Article Title: Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy

    Journal: bioRxiv

    doi: 10.1101/2021.07.20.452858

    In vitro screening of Abs against SARS-CoV-2 variants of concern. (a) Binding to cell-associated spike trimer with the hallmark mutations of the specified variants. (b) ELISA results to plate-adsorbed recombinant spike proteins and (c) heat map summary of ELISA-based reactivity profiles.
    Figure Legend Snippet: In vitro screening of Abs against SARS-CoV-2 variants of concern. (a) Binding to cell-associated spike trimer with the hallmark mutations of the specified variants. (b) ELISA results to plate-adsorbed recombinant spike proteins and (c) heat map summary of ELISA-based reactivity profiles.

    Techniques Used: In Vitro, Binding Assay, Enzyme-linked Immunosorbent Assay, Recombinant

    Hamster challenge model for SARS-CoV-2 infection. (a) Study design (see Methods) . Primary measures of in vivo efficacy of cocktails and individual Abs in blends TATX-03a (b,c) and TATX-03b (d,e) . TATX-03a (23-H7, 22-D9, 22-E7, 2-A6) was administered pre-challenge (prophylactic, PPx) or post-challenge (therapeutic, Tx) as indicated at 40 mg/kg total Ab concentration (10 mg/kg/Ab in the 4-Ab blend), while the individual Abs of TATX-03a were on administered pre-challenge at 40 mg/kg. TATX-03b (23-H7, 21-F2, 22-F7, 2-A6) was administered at 20 mg/kg total Ab concentration (5 mg/kg/Ab in the 4-Ab blend) as Tx only. Individual antibodies were administered post-challenge at 20 mg/kg (23-H7, 21-F2 and 22-F7) and 5 mg/kg (23-H7 and 21-F2). In addition, one group was post-challenge treated with a 2-Ab combination of 23-H7 and 21-F2 at 5 mg/kg total Ab concentration (2.5 mg/kg/Ab). Replication-competent viral titers (Log10 Median Tissue Culture Infective Dose (TCID50) in (b,d) throat swab (day 3 post-infection; lowest level of detection, LLOD = 0.8) and (c,e) lung (day 4 post-infection, endpoint; LLOD = 1.3). Statistics are described in Methods. *p
    Figure Legend Snippet: Hamster challenge model for SARS-CoV-2 infection. (a) Study design (see Methods) . Primary measures of in vivo efficacy of cocktails and individual Abs in blends TATX-03a (b,c) and TATX-03b (d,e) . TATX-03a (23-H7, 22-D9, 22-E7, 2-A6) was administered pre-challenge (prophylactic, PPx) or post-challenge (therapeutic, Tx) as indicated at 40 mg/kg total Ab concentration (10 mg/kg/Ab in the 4-Ab blend), while the individual Abs of TATX-03a were on administered pre-challenge at 40 mg/kg. TATX-03b (23-H7, 21-F2, 22-F7, 2-A6) was administered at 20 mg/kg total Ab concentration (5 mg/kg/Ab in the 4-Ab blend) as Tx only. Individual antibodies were administered post-challenge at 20 mg/kg (23-H7, 21-F2 and 22-F7) and 5 mg/kg (23-H7 and 21-F2). In addition, one group was post-challenge treated with a 2-Ab combination of 23-H7 and 21-F2 at 5 mg/kg total Ab concentration (2.5 mg/kg/Ab). Replication-competent viral titers (Log10 Median Tissue Culture Infective Dose (TCID50) in (b,d) throat swab (day 3 post-infection; lowest level of detection, LLOD = 0.8) and (c,e) lung (day 4 post-infection, endpoint; LLOD = 1.3). Statistics are described in Methods. *p

    Techniques Used: Infection, In Vivo, Concentration Assay

    Cell-based reactivity and pseudovirus neutralization screening against the variants of concern (VOCs) (a) Heat map summarizing the complementary vulnerabilities of indicated clones of the TATX-03 cocktail against cell-associated spike trimers expressing Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), B.1.429, and B.1.526 mutants. Corresponding dose-response graphs are shown in Supplemental Fig 6a . (b ) In vitro virus neutralization screenings of TATX-03a-c c using VSV-particles pseudo-typed with spike proteins representing the original Wuhan-1 isolate and SARS-CoV-2 variants of concern Alpha, Beta, and Delta..
    Figure Legend Snippet: Cell-based reactivity and pseudovirus neutralization screening against the variants of concern (VOCs) (a) Heat map summarizing the complementary vulnerabilities of indicated clones of the TATX-03 cocktail against cell-associated spike trimers expressing Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), B.1.429, and B.1.526 mutants. Corresponding dose-response graphs are shown in Supplemental Fig 6a . (b ) In vitro virus neutralization screenings of TATX-03a-c c using VSV-particles pseudo-typed with spike proteins representing the original Wuhan-1 isolate and SARS-CoV-2 variants of concern Alpha, Beta, and Delta..

    Techniques Used: Neutralization, Clone Assay, Expressing, In Vitro

    IPA’s library-to-leads triage process. (a) High-level schematic of the workflow. (b) Heat map for a pairwise analysis of 19 library-derived anti-SARS-CoV-2 S1-specific Abs merged with a panel of ten structural benchmarks (9 literature Abs and ACE2). The red, yellow, and green colored cells indicate Ab pairs that are blocked (b), partially blocked (pb), or not blocked (nb), respectively. Colored cells with a designation of “b, pb, or nb” were measured empirically, whereas those without a designation are “inferred”. The black boxed cells along the diagonal indicate the “self-blocked” pairs. In our bin-definition, bin-members block one another and show similar blocking behaviors when tested against other Abs in the panel. RBD-specific clones were assigned to five bins (1-5). RBD binders that did not block ACE2 were assigned bin “1”, which was split into sub-bins (bin 1a, 1b, and 1c) based on their nuanced blockade towards the structural benchmarks ( Supplemental Fig S1 ). A cluster of S1 non-RBD binders blocked bin 1 (but not the sub-bins) and did not block any of the literature Abs, so were assigned to bin “C”, representing the C-terminal nub of the S1 fragment, between the RBD and the furin cleavage site, distinct from the N-terminal domain (NTD); hence, bin C’s specificity is assigned as S1-nonRBD-nonNTD. One RBD-binder Ab (23-H7) blocked bin 1, REGN10987 and uniquely perturbed/partially blocked ACE2 ( Supplemental Fig S2 ) , so was assigned to bin 2. Within the ACE2 fully blocking clones, we identified two discrete sets of Abs (bin 4 and bin 5); bin 4 co-located with REGN10933 and CB6, while bin 5 co-located with the “cryptic” epitope of CR3022, VHH-72 and SB68. Bin 3 blocked both bin 2 (23-H7) and bin 4. (c) Image of the spike trimer and zoomed in view of the RBD in grey (PDB ID: 7BNM residues 330-520) showing the epitope contacts for benchmark Abs CR3022 (red, PDB ID: 6YMO) REGN10987 (orange, PDB ID: 6XDG), REGN10933 (blue, PDB ID: 6XDG), CB6 (yellow, PDB ID: 7C01), and REGN10933/CB6 shared residues in green. Depiction of the benchmark “bald spot” present on the RBD, an area of the Spike where none of the available literature controls bound. The C terminus of S1-nonRBD is shaded darker grey (residues 320-329; 521-593). Predicted epitope regions for Abs assigned to bin C, bin 1 and sub-bins 1a, 1b, and 1c (dotted ovals) are also indicated. RBD and benchmark antibody structures were imported from PDB to Maestro. Proteins were aligned via Protein Structure Alignment. (d) Color wheel showing the composition of TATX-03 blends comprised from six lead Abs distributed across four distinct bins.
    Figure Legend Snippet: IPA’s library-to-leads triage process. (a) High-level schematic of the workflow. (b) Heat map for a pairwise analysis of 19 library-derived anti-SARS-CoV-2 S1-specific Abs merged with a panel of ten structural benchmarks (9 literature Abs and ACE2). The red, yellow, and green colored cells indicate Ab pairs that are blocked (b), partially blocked (pb), or not blocked (nb), respectively. Colored cells with a designation of “b, pb, or nb” were measured empirically, whereas those without a designation are “inferred”. The black boxed cells along the diagonal indicate the “self-blocked” pairs. In our bin-definition, bin-members block one another and show similar blocking behaviors when tested against other Abs in the panel. RBD-specific clones were assigned to five bins (1-5). RBD binders that did not block ACE2 were assigned bin “1”, which was split into sub-bins (bin 1a, 1b, and 1c) based on their nuanced blockade towards the structural benchmarks ( Supplemental Fig S1 ). A cluster of S1 non-RBD binders blocked bin 1 (but not the sub-bins) and did not block any of the literature Abs, so were assigned to bin “C”, representing the C-terminal nub of the S1 fragment, between the RBD and the furin cleavage site, distinct from the N-terminal domain (NTD); hence, bin C’s specificity is assigned as S1-nonRBD-nonNTD. One RBD-binder Ab (23-H7) blocked bin 1, REGN10987 and uniquely perturbed/partially blocked ACE2 ( Supplemental Fig S2 ) , so was assigned to bin 2. Within the ACE2 fully blocking clones, we identified two discrete sets of Abs (bin 4 and bin 5); bin 4 co-located with REGN10933 and CB6, while bin 5 co-located with the “cryptic” epitope of CR3022, VHH-72 and SB68. Bin 3 blocked both bin 2 (23-H7) and bin 4. (c) Image of the spike trimer and zoomed in view of the RBD in grey (PDB ID: 7BNM residues 330-520) showing the epitope contacts for benchmark Abs CR3022 (red, PDB ID: 6YMO) REGN10987 (orange, PDB ID: 6XDG), REGN10933 (blue, PDB ID: 6XDG), CB6 (yellow, PDB ID: 7C01), and REGN10933/CB6 shared residues in green. Depiction of the benchmark “bald spot” present on the RBD, an area of the Spike where none of the available literature controls bound. The C terminus of S1-nonRBD is shaded darker grey (residues 320-329; 521-593). Predicted epitope regions for Abs assigned to bin C, bin 1 and sub-bins 1a, 1b, and 1c (dotted ovals) are also indicated. RBD and benchmark antibody structures were imported from PDB to Maestro. Proteins were aligned via Protein Structure Alignment. (d) Color wheel showing the composition of TATX-03 blends comprised from six lead Abs distributed across four distinct bins.

    Techniques Used: Indirect Immunoperoxidase Assay, Derivative Assay, Blocking Assay, Clone Assay

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Sino Biological sars cov 2 2019 ncov spike rbd k417n his recombinant protein
    In vitro screening of Abs against <t>SARS-CoV-2</t> variants of concern. (a) Binding to cell-associated spike trimer with the hallmark mutations of the specified variants. (b) ELISA results to plate-adsorbed recombinant spike proteins and (c) heat map summary of ELISA-based reactivity profiles.
    Sars Cov 2 2019 Ncov Spike Rbd K417n His Recombinant Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike rbd k417n his recombinant protein/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike rbd k417n his recombinant protein - by Bioz Stars, 2021-09
    94/100 stars
      Buy from Supplier

    Image Search Results


    In vitro screening of Abs against SARS-CoV-2 variants of concern. (a) Binding to cell-associated spike trimer with the hallmark mutations of the specified variants. (b) ELISA results to plate-adsorbed recombinant spike proteins and (c) heat map summary of ELISA-based reactivity profiles.

    Journal: bioRxiv

    Article Title: Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy

    doi: 10.1101/2021.07.20.452858

    Figure Lengend Snippet: In vitro screening of Abs against SARS-CoV-2 variants of concern. (a) Binding to cell-associated spike trimer with the hallmark mutations of the specified variants. (b) ELISA results to plate-adsorbed recombinant spike proteins and (c) heat map summary of ELISA-based reactivity profiles.

    Article Snippet: Various spike protein subunits including S1-mFc, S1-hFc, S2-hFc, NTD-hFc, S1-S2-His, S1-His, and mutants S1-His(D614G), S. African B.1.351 lineage S1-His(K417N, E484K, N501Y, D614G), S1-His(HV69-70del, N501Y, D614G), UK S1-His(HV69-70del, Y144del, N501Y, A570D, D614G, P681H) were purchased from Sino Biological (cat# 40591-V05H1, 40591-V02H, 40590-V02H, 40591-V41H, V0589-V08B1, 40591-VO8H, 40591-V08H3, 40591-V08H10, 40591-V08H7, 40591-V08H12, respectively) as well as RBD single point mutants (A435S, F342L, G476S, K458R, N354D, N439K, S477N, V367F, V483A, W436R, E484K, K417N, Y453F, N501Y; cat# 40592-V08H4, 40592-V08H6, 40592-V08H8, 40592-V08H7, 40592-V08H2, 40592-V08H14, 40592-V08H46, 40592-V08H1, 40592-V08H5, 40592-V08H9, 40592-V08H84, 40592-V08H59, 40592-V08H80, 40592-V08H82, respectively).

    Techniques: In Vitro, Binding Assay, Enzyme-linked Immunosorbent Assay, Recombinant

    Hamster challenge model for SARS-CoV-2 infection. (a) Study design (see Methods) . Primary measures of in vivo efficacy of cocktails and individual Abs in blends TATX-03a (b,c) and TATX-03b (d,e) . TATX-03a (23-H7, 22-D9, 22-E7, 2-A6) was administered pre-challenge (prophylactic, PPx) or post-challenge (therapeutic, Tx) as indicated at 40 mg/kg total Ab concentration (10 mg/kg/Ab in the 4-Ab blend), while the individual Abs of TATX-03a were on administered pre-challenge at 40 mg/kg. TATX-03b (23-H7, 21-F2, 22-F7, 2-A6) was administered at 20 mg/kg total Ab concentration (5 mg/kg/Ab in the 4-Ab blend) as Tx only. Individual antibodies were administered post-challenge at 20 mg/kg (23-H7, 21-F2 and 22-F7) and 5 mg/kg (23-H7 and 21-F2). In addition, one group was post-challenge treated with a 2-Ab combination of 23-H7 and 21-F2 at 5 mg/kg total Ab concentration (2.5 mg/kg/Ab). Replication-competent viral titers (Log10 Median Tissue Culture Infective Dose (TCID50) in (b,d) throat swab (day 3 post-infection; lowest level of detection, LLOD = 0.8) and (c,e) lung (day 4 post-infection, endpoint; LLOD = 1.3). Statistics are described in Methods. *p

    Journal: bioRxiv

    Article Title: Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy

    doi: 10.1101/2021.07.20.452858

    Figure Lengend Snippet: Hamster challenge model for SARS-CoV-2 infection. (a) Study design (see Methods) . Primary measures of in vivo efficacy of cocktails and individual Abs in blends TATX-03a (b,c) and TATX-03b (d,e) . TATX-03a (23-H7, 22-D9, 22-E7, 2-A6) was administered pre-challenge (prophylactic, PPx) or post-challenge (therapeutic, Tx) as indicated at 40 mg/kg total Ab concentration (10 mg/kg/Ab in the 4-Ab blend), while the individual Abs of TATX-03a were on administered pre-challenge at 40 mg/kg. TATX-03b (23-H7, 21-F2, 22-F7, 2-A6) was administered at 20 mg/kg total Ab concentration (5 mg/kg/Ab in the 4-Ab blend) as Tx only. Individual antibodies were administered post-challenge at 20 mg/kg (23-H7, 21-F2 and 22-F7) and 5 mg/kg (23-H7 and 21-F2). In addition, one group was post-challenge treated with a 2-Ab combination of 23-H7 and 21-F2 at 5 mg/kg total Ab concentration (2.5 mg/kg/Ab). Replication-competent viral titers (Log10 Median Tissue Culture Infective Dose (TCID50) in (b,d) throat swab (day 3 post-infection; lowest level of detection, LLOD = 0.8) and (c,e) lung (day 4 post-infection, endpoint; LLOD = 1.3). Statistics are described in Methods. *p

    Article Snippet: Various spike protein subunits including S1-mFc, S1-hFc, S2-hFc, NTD-hFc, S1-S2-His, S1-His, and mutants S1-His(D614G), S. African B.1.351 lineage S1-His(K417N, E484K, N501Y, D614G), S1-His(HV69-70del, N501Y, D614G), UK S1-His(HV69-70del, Y144del, N501Y, A570D, D614G, P681H) were purchased from Sino Biological (cat# 40591-V05H1, 40591-V02H, 40590-V02H, 40591-V41H, V0589-V08B1, 40591-VO8H, 40591-V08H3, 40591-V08H10, 40591-V08H7, 40591-V08H12, respectively) as well as RBD single point mutants (A435S, F342L, G476S, K458R, N354D, N439K, S477N, V367F, V483A, W436R, E484K, K417N, Y453F, N501Y; cat# 40592-V08H4, 40592-V08H6, 40592-V08H8, 40592-V08H7, 40592-V08H2, 40592-V08H14, 40592-V08H46, 40592-V08H1, 40592-V08H5, 40592-V08H9, 40592-V08H84, 40592-V08H59, 40592-V08H80, 40592-V08H82, respectively).

    Techniques: Infection, In Vivo, Concentration Assay

    IPA’s library-to-leads triage process. (a) High-level schematic of the workflow. (b) Heat map for a pairwise analysis of 19 library-derived anti-SARS-CoV-2 S1-specific Abs merged with a panel of ten structural benchmarks (9 literature Abs and ACE2). The red, yellow, and green colored cells indicate Ab pairs that are blocked (b), partially blocked (pb), or not blocked (nb), respectively. Colored cells with a designation of “b, pb, or nb” were measured empirically, whereas those without a designation are “inferred”. The black boxed cells along the diagonal indicate the “self-blocked” pairs. In our bin-definition, bin-members block one another and show similar blocking behaviors when tested against other Abs in the panel. RBD-specific clones were assigned to five bins (1-5). RBD binders that did not block ACE2 were assigned bin “1”, which was split into sub-bins (bin 1a, 1b, and 1c) based on their nuanced blockade towards the structural benchmarks ( Supplemental Fig S1 ). A cluster of S1 non-RBD binders blocked bin 1 (but not the sub-bins) and did not block any of the literature Abs, so were assigned to bin “C”, representing the C-terminal nub of the S1 fragment, between the RBD and the furin cleavage site, distinct from the N-terminal domain (NTD); hence, bin C’s specificity is assigned as S1-nonRBD-nonNTD. One RBD-binder Ab (23-H7) blocked bin 1, REGN10987 and uniquely perturbed/partially blocked ACE2 ( Supplemental Fig S2 ) , so was assigned to bin 2. Within the ACE2 fully blocking clones, we identified two discrete sets of Abs (bin 4 and bin 5); bin 4 co-located with REGN10933 and CB6, while bin 5 co-located with the “cryptic” epitope of CR3022, VHH-72 and SB68. Bin 3 blocked both bin 2 (23-H7) and bin 4. (c) Image of the spike trimer and zoomed in view of the RBD in grey (PDB ID: 7BNM residues 330-520) showing the epitope contacts for benchmark Abs CR3022 (red, PDB ID: 6YMO) REGN10987 (orange, PDB ID: 6XDG), REGN10933 (blue, PDB ID: 6XDG), CB6 (yellow, PDB ID: 7C01), and REGN10933/CB6 shared residues in green. Depiction of the benchmark “bald spot” present on the RBD, an area of the Spike where none of the available literature controls bound. The C terminus of S1-nonRBD is shaded darker grey (residues 320-329; 521-593). Predicted epitope regions for Abs assigned to bin C, bin 1 and sub-bins 1a, 1b, and 1c (dotted ovals) are also indicated. RBD and benchmark antibody structures were imported from PDB to Maestro. Proteins were aligned via Protein Structure Alignment. (d) Color wheel showing the composition of TATX-03 blends comprised from six lead Abs distributed across four distinct bins.

    Journal: bioRxiv

    Article Title: Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy

    doi: 10.1101/2021.07.20.452858

    Figure Lengend Snippet: IPA’s library-to-leads triage process. (a) High-level schematic of the workflow. (b) Heat map for a pairwise analysis of 19 library-derived anti-SARS-CoV-2 S1-specific Abs merged with a panel of ten structural benchmarks (9 literature Abs and ACE2). The red, yellow, and green colored cells indicate Ab pairs that are blocked (b), partially blocked (pb), or not blocked (nb), respectively. Colored cells with a designation of “b, pb, or nb” were measured empirically, whereas those without a designation are “inferred”. The black boxed cells along the diagonal indicate the “self-blocked” pairs. In our bin-definition, bin-members block one another and show similar blocking behaviors when tested against other Abs in the panel. RBD-specific clones were assigned to five bins (1-5). RBD binders that did not block ACE2 were assigned bin “1”, which was split into sub-bins (bin 1a, 1b, and 1c) based on their nuanced blockade towards the structural benchmarks ( Supplemental Fig S1 ). A cluster of S1 non-RBD binders blocked bin 1 (but not the sub-bins) and did not block any of the literature Abs, so were assigned to bin “C”, representing the C-terminal nub of the S1 fragment, between the RBD and the furin cleavage site, distinct from the N-terminal domain (NTD); hence, bin C’s specificity is assigned as S1-nonRBD-nonNTD. One RBD-binder Ab (23-H7) blocked bin 1, REGN10987 and uniquely perturbed/partially blocked ACE2 ( Supplemental Fig S2 ) , so was assigned to bin 2. Within the ACE2 fully blocking clones, we identified two discrete sets of Abs (bin 4 and bin 5); bin 4 co-located with REGN10933 and CB6, while bin 5 co-located with the “cryptic” epitope of CR3022, VHH-72 and SB68. Bin 3 blocked both bin 2 (23-H7) and bin 4. (c) Image of the spike trimer and zoomed in view of the RBD in grey (PDB ID: 7BNM residues 330-520) showing the epitope contacts for benchmark Abs CR3022 (red, PDB ID: 6YMO) REGN10987 (orange, PDB ID: 6XDG), REGN10933 (blue, PDB ID: 6XDG), CB6 (yellow, PDB ID: 7C01), and REGN10933/CB6 shared residues in green. Depiction of the benchmark “bald spot” present on the RBD, an area of the Spike where none of the available literature controls bound. The C terminus of S1-nonRBD is shaded darker grey (residues 320-329; 521-593). Predicted epitope regions for Abs assigned to bin C, bin 1 and sub-bins 1a, 1b, and 1c (dotted ovals) are also indicated. RBD and benchmark antibody structures were imported from PDB to Maestro. Proteins were aligned via Protein Structure Alignment. (d) Color wheel showing the composition of TATX-03 blends comprised from six lead Abs distributed across four distinct bins.

    Article Snippet: Various spike protein subunits including S1-mFc, S1-hFc, S2-hFc, NTD-hFc, S1-S2-His, S1-His, and mutants S1-His(D614G), S. African B.1.351 lineage S1-His(K417N, E484K, N501Y, D614G), S1-His(HV69-70del, N501Y, D614G), UK S1-His(HV69-70del, Y144del, N501Y, A570D, D614G, P681H) were purchased from Sino Biological (cat# 40591-V05H1, 40591-V02H, 40590-V02H, 40591-V41H, V0589-V08B1, 40591-VO8H, 40591-V08H3, 40591-V08H10, 40591-V08H7, 40591-V08H12, respectively) as well as RBD single point mutants (A435S, F342L, G476S, K458R, N354D, N439K, S477N, V367F, V483A, W436R, E484K, K417N, Y453F, N501Y; cat# 40592-V08H4, 40592-V08H6, 40592-V08H8, 40592-V08H7, 40592-V08H2, 40592-V08H14, 40592-V08H46, 40592-V08H1, 40592-V08H5, 40592-V08H9, 40592-V08H84, 40592-V08H59, 40592-V08H80, 40592-V08H82, respectively).

    Techniques: Indirect Immunoperoxidase Assay, Derivative Assay, Blocking Assay, Clone Assay